DCs are exceptionally powerful initiators of immunity, with the ability to activate an immune response more potently than any other cell in the immune repertoire. Dendritic cells are a type of antigen presenting cells (APC) that play an important role in the adaptive immune system. They have the capacity to induce a primary immune response in the inactive or resting naïve T lymphocytes. To do this DCs capture antigens from invading bodies, which they process and present on their cell surface along with the necessary co-stimulation molecules. They also contribute to the function of B cells and help maintain their immune memory. Cancer malignancies are often treated by administering a DC vaccine during the premalignant stages, prior to development of immune suppression. RGCCs laboratories use patients’ isolated monocytes as a source for the in vitro production of DCs. DCs are then pulsed with synthesized peptides that are dependent on the antigens expressed on the cancer cells from each patient. This way we are able to obtain mature DCs specific for a patient’s tumor antigens, leading to a more personalized treatment.